ERBB2 and gastric cancer: The addition of trastuzumab, an antibody inhibitor of human epidermal growth factor receptor 2 (HER-2), to pembrolizumab and chemotherapy in the treatment of HER-2-positive gastric cancer also markedly reduced the tumor size and significantly improved the objective response rate (22).